SPONSOR
Grit Biotechnology
Total Trials
3
Recruiting
3
Phases
Phase 2, Phase 1
Grit Biotechnology is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Adult, Recurrent or Metastatic Cervical Cancer, Neurological Autoimmune Diseases.
The trial portfolio spans Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Grit Biotechnology
How many clinical trials has Grit Biotechnology sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Grit Biotechnology, of which 3 are actively recruiting participants. These trials cover conditions including Adult, Recurrent or Metastatic Cervical Cancer, Neurological Autoimmune Diseases. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Grit Biotechnology research focus on?
Grit Biotechnology clinical trials span Adult, Recurrent or Metastatic Cervical Cancer, Neurological Autoimmune Diseases. The research pipeline includes Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Grit Biotechnology clinical trial?
To participate in a Grit Biotechnology trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Grit Biotechnology trials with current recruitment status updated daily.
Clinical Trials by Grit Biotechnology
NCT06819280
Recruiting
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer
Adult
NCT06241781 Phase 2
Recruiting
Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer
Recurrent or Metastatic Cervical Cancer
NCT07021209 Phase 1
Recruiting
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
Neurological Autoimmune Diseases
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology